JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Identification and evaluation of fragmentation pathways of PDE-5 inhibitor analogues using LC-QTOF-MS
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Analytical Science and Technology
  • Volume 28, Issue 4,  2015, pp.278-287
  • Publisher : The Korean Society of Analytical Science
  • DOI : 10.5806/AST.2015.28.4.278
 Title & Authors
Identification and evaluation of fragmentation pathways of PDE-5 inhibitor analogues using LC-QTOF-MS
Do, Jung-Ah; Noh, Eunyoung; Yoon, Soon-Byung; Park, Hyoung-Joon; Cho, Sooyeul; Park, Sung-Kwan; Yoon, Chang-Yong;
  PDF(new window)
 Abstract
Phosphodiesterase type 5 inhibitors (PDE-5 inhibitors) are used in the treatment of erectile dysfunction. In recent years, a number of reports have been conducted on dietary supplements contaminated with PDE-5 analogues. In this study, 58 analogues of PDE-5 inhibitors were sorted into five groups: tadalafil, sildenafil, hongdenafil, vardenafil, and other analogues. These analogues were then evaluated using a liquid chromatography-quadrupole-time of flight mass spectrometry (LC-QTOF-MS) electrospray ionization mass method. Each compound has a unique fragmentation ion, which can be easily analyzed qualitatively. The fragmentation pathways of the analogues were elucidated based on the QTOF-MS and MS/MS data. Common ions were confirmed for each group by analyzing the structural characteristics and fragmentation pathways. Specifically, common ions were observed at m/z 169.08 and 135.04 (tadalafil analogues), m/z 311.15 and 283.12 (sildenafil analogues and hongdenafil analogues), and m/z 312.16 and 151.09 (vardenafil analogues). The advantage of this method is that the structure of unknown components can be determined by interpreting the product ions. Hence, the developed method can be used for the identification of unknown compounds. Fragmentation pathways may also aid in the detection and identification of PDE-5 inhibitor analogues.
 Keywords
PDE-5;LC-QTOF-MS;fragmentation pathway;identification;unknown compounds;
 Language
English
 Cited by
 References
1.
B. J. Venhuis, G. Zomer, M. Hamzink, H. D. Meiring, Y. Aubin and D. de Kaste, J. Pharm. Biomed. Anal., 54(4), 735-741 (2011). crossref(new window)

2.
L. Blok-Tip, B. Zomer, F. Bakker, K. D. Hartog, M. Hamzink, J. Ten Hove, M. Vredenbregt, D. de Kaste, Food Addit. Contam., 21(8), 737-748 (2004). crossref(new window)

3.
Q. Liang, J. Qu, G. Luo and Y. Wang, J. Pharm. Biomed. Anal., 40(2), 305-311 (2006). crossref(new window)

4.
S. R. Gratz, C. L. Flurer and K. A. Wolnik, J. Pharm. Biomed. Anal., 36(3), 525-533 (2004). crossref(new window)

5.
M. H. Shin, M. K. Hong, W. S. Kim, Y. J. Lee and Y. C. Jeoung, Food Addit. Contam., 20(9), 793-798 (2003). crossref(new window)

6.
R. Yuan and Y. Lin, Pharmacol. Ther., 86(2), 191-198 (2000). crossref(new window)

7.
FDA approves Stendra for erectile dysfunction, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302140.htm/, Assessed 13 Jan 2001.

8.
O. Shaeer. The Global Online Sexuality Survey (GOSS): The United States of America in 2011 Chapter II: phosphodiesterase inhibitors utilization among English speakers. J. Sex. Med., 10(2), 532-540 (2012).

9.
A. W. Shindel. Update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J. Sex. Med., 6, 2352-2364 (2009). crossref(new window)

10.
C. G. Stief, S. Uckert, A. J. Becker, M. C. Truss and U. Jonas, J. Urol., 159(4), 1390-1393 (1998). crossref(new window)

11.
B. J. Venhuis and D. Kaste, J. Pharm. Biomed. Anal., 69, 196-208 (2012). crossref(new window)

12.
M. Y. Low, Y. Zeng, L. Li, X. W. Ge, R. Lee and B. C. Bloodworth, H. L. Koh, Drug Saf., 32(12), 1141-1146 (2009). crossref(new window)

13.
Illicit erectile dysfunction products in the Netherlands http://www.rivm.nl/Documenten_en_publicaties/Wetenschappelijk/Rapporten/2011/september/Illicit_erectile_dysfunction_products_in_the_Netherlands_A_decade_of_trends_and_a_2007_2010_product_update/, Assessed 8 Sept 2011.

14.
M. Sugita and M. Miyakawa, Health Preventive Med., 15(4), 244-251 (2010). crossref(new window)

15.
S. Singh, B. Prasad, A. A. Savaliya, R. P. Shah and V. M. Gohil, A. Kaur, Trends Anal. Chem., 28(1), 13-28 (2009). crossref(new window)

16.
J. B. Guo, Y. Xu, Z. B. Huang, Q. H. He, S. W. Liu, Anal. Chim., 658(2), 197-203 (2010). crossref(new window)

17.
S. M. Khalil, Microchim., 158, 233-238 (2007). crossref(new window)

18.
C. M. Gryniewicz, J. C. Reepmeyer, J. F. Kauffman and L. F. Buhse, J. Pharm. Biomed. Anal., 49(3), 601-606 (2009). crossref(new window)

19.
D. J. Mans, R. J. Callahan, J. D. Dunn and C. M. Gryniewicz-Ruzicka, J. Pharm. Biomed. Anal., 75(5), 153-157 (2013). crossref(new window)

20.
D. Z. Mao, X. X. Weng and Y. J. Yang, J. Raman Spectrosc., 43(12), 1985-1990 (2012). crossref(new window)

21.
C. L. Cheng, G. J. Kang and C. H. Chou, J. Chromatogr., 1154(1-2), 222-229 (2007). crossref(new window)

22.
M. Park and S. Ahn, J. Forensic Sci., 57(6), 1637-1640 (2012). crossref(new window)

23.
P. Y. Sacre, E. Deconinck, P. Chiap, J. Crommen, F. Mansion, E. Rozet, P. Courselle and J. O. De Beer, J. Chromatogr., 1218(37), 6439-6447 (2011). crossref(new window)

24.
C. N. Man, N. M. Noor and R. Lajis, J. Chromatogr., 1218(39), 7055-7060 (2011). crossref(new window)

25.
P. Nikolaou, I. Papoutsis, S. Athanaselis, G. Alevisopoulos, A. Khraiwesh, C. Pistos and C. Spiliopoulou, J. Pharm. Biomed. Anal., 56(3), 577-581 (2011). crossref(new window)

26.
R. Patterson, P. Mabe, E. N. Mitchell and W. Cory, Forensic Sci. Int., 222(1-3), 83-88 (2012). crossref(new window)

27.
C. S. Ng, T. Y. Law, Y. K. Cheung, P. C. Ng and K. K. Choi, Anal. Methods., 2, 890-896 (2010). crossref(new window)

28.
Y. Ren, C. S. Wu and J. L. Zhang, J. Sep. Sci., 35(21), 2847-2857 (2012). crossref(new window)

29.
M. E. Hadwiger, M. L. Trehy, W. Ye, T. Moore, J. Allgire and B. Westenberger, J. Chromatogr. A., 1217(48), 7547-7555 (2010). crossref(new window)

30.
Y. Cai, T. G. Cai, Y. Shi, X. L. Cheng, L. Y. Ma, S. C. Ma, R. C. Lin and W. Feng, J. Liq. Chromatogr. Rel. Technol., 33, 1287-1306 (2010). crossref(new window)

31.
A. Lanzarotta, J. B. Crowe, M. Witkowski and B. M. Gamble, J. Pharm. Biomed. Anal., 67-68, 22-27 (2012). crossref(new window)

32.
F. W. McLafferty. Interpretation of Mass Spectra, third edition. University Science Books, p 51-215, Mill Valley, California, 1980.

33.
J. H. Lee, H. J. Kim, E. Noh, J. Y. Kim, S. H. Cho, J.-A Do, C.-Y. Yoon, S. Cho and W. S. Kim, J. Pharm. Biomed. Anal., 103, 80-84 (2015). crossref(new window)